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CASE REPORT

Tuberculous Pericarditis
Chun-Kit Wong*, Yeuk-Chi Choi
Department of Medicine & Geriatrics, Princess Margaret Hospital, Hong Kong

Abstract
Tuberculous (TB) pericarditis, a severe extrapulmonary manifestation of Mycobacterium tuberculosis, is notorious for
its challenging presentation. We report a case of effusive-constrictive pericarditis due to tuberculosis infection.
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Introduction

M

ycobacterium tuberculosis (MTB) is notorious
for its extrapulmonary involvement. Cardiac
involvement, in the form of effusive-constrictive
pericarditis, has been scarcely described in the
literature. We report a case of tuberculous pericarditis, successfully managed after timely echocardiographic, microbiological, and endoscopic
workup.

Case report
A 63-year-old man was admitted to the intensive
care unit for high fever and shortness of breath. He
reported increasing exertional dyspnea and lower
limb swelling for one week. On admission, the white
cell count was normal (8.2  109/L); there was mild
anemia (hemoglobin 12.1 g/dL), with a high erythrocyte sedimentation rate (103 mm/hr). His renal
function was normal (creatinine 61 mmol/L), and
there were elevated liver enzymes (alkaline phosphatase 142 U/L, alanine aminotransferase 89 U/L).
Electrocardiogram demonstrated low voltage over
limb leads, and the chest X-ray showed gross cardiomegaly. Bedside focused echocardiogram to
evaluate cardiomegaly found massive circumferential pericardial effusion, more than 4 cm measured

from the apical window, which quickly led to a
pericardiocentesis draining around 2 L of bloodstained pericardial ﬂuid.
However, the patient's clinical condition
continued to deteriorate despite drainage of pericardial effusion, with worsening respiratory distress
and multiorgan dysfunction. Urgent tracing of the
biochemistry of pericardial ﬂuid revealed an
exudative nature, with high protein (55 g/L) and
lactate dehydrogenase level (521 U/L); however,
bacterial culture, acid-fast bacilli smear, MTB PCR
of the pericardial ﬂuid were negative. The only hint
of MTB as a unifying diagnosis over other differentials e.g. rheumatological disease or neoplastic
processes was an elevated pericardial adenosine
deaminase (ADA) level up to 45 U/L, with a cut off
quoted to be 40 U/L.
Urgent computed tomography of the thorax with
contrast was ordered, which revealed apart from
nonspeciﬁc consolidative changes of lung parenchyma, multiple prominent paraaortic, paratracheal
and hilar lymph nodes, with the largest one
measuring 2.3 cm in the right paratracheal region.
Thickened pericardium with contrast enhancement
was suggestive of active pericarditis. Repeat transthoracic echocardiogram showed interval reduction
of pericardial effusion (Figure 1), but overt
constrictive features: septal bounce, dilation of both
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Figure 1. Side-by-side pre- and post-treatment echocardiographic still frames for comparison. Pericardial thickening and pericardial effusion are
evident before treatment. PLAX: parasternal long axis view. PSAX: parasternal short axis view. A4C: apical four-chamber view.

atria with congested inferior vena cava, exaggerated
respiro-phasic changes of mitral, tricuspid, and
pulmonary vein diastolic inﬂow (Figure 2), expiratory diastolic ﬂow reversal in hepatic vein (Figure 3),
annulus reversus, and pulsus paradoxus, consistent
of an effusive-constrictive physiology, and thus
explaining the clinical deterioration with pulmonary
congestion and hepatic and renal derangement.
Bronchoscopy was scheduled urgently as microbiological proof is the key. No endobronchial lesions

were noted upon examination of the airway; bronchoalveolar lavage was performed to the right upper
lobe; and lastly endobronchial ultrasound was able to
guide needle biopsy of the right paratracheal lymph
node transbronchially. It was the lymph node that
ﬁnally gave microbiological proof of MTB, with MTB
PCR positive in the cell block and histology showing
granuloma. Antimicrobials were streamlined to
amikacin, ethambutol, and levoﬂoxacin; and corticosteroids, initially with intravenous hydrocortisone
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Figure 2. Exaggerated respirophasic variation in mitral E wave and diastolic pulmonary vein inﬂow before treatment. After treatment, a reversed E/A
ratio is uncovered, suggestive of preexisting Grade 1 diastolic dysfunction, and a normal pulmonary vein systolic and diastolic inﬂow pattern
resumed.

100 mg every eight hours, was started for effusiveconstrictive pericarditis.
The patient improved rapidly after commencement
of anti-tuberculous medications and corticosteroids,
weaning off noninvasive ventilation support, and
evaded the need of acute dialysis. His organ parameters normalized, and standard anti-tuberculous
therapy was introduced carefully, using isoniazid,
rifampicin, ethambutol and levoﬂoxacin. 1 week after
the introduction of rifampicin, a strong enzyme
inducer, moderate doses of hydrocortisone were
switched to oral prednisolone at 0.5 mg/kg/day,
tapering by 10 mg/day each week over 4 weeks, while
carefully monitoring for any rebound inﬂammation.
Progress echocardiogram showed resolution of all
constrictive features; right heart catheterization was
deemed not necessary due to dramatic clinical
improvement. The patient was discharged at week 3
of hospitalization. On clinical follow up subsequently,
Mycobacterium tuberculosis was grown from pericardial ﬂuid and paratracheal lymph node.

Discussion
This case illustrates the difﬁculty of diagnosing
extrapulmonary Mycobacterium tuberculosis infection,
and the race with time in attaining microbiological
proof of tuberculosis before correct treatment can be
initiated. The laboratory use of adenosine deaminase
level in pericardial ﬂuid aids to reduce diagnostic
uncertainties, by providing clear cutoff with acceptable sensitivity (88%) and speciﬁcity (83%) [1]. PCR
tests of MTB DNA have further reduced the time in
diagnosis.
The diagnosis of constrictive pericarditis has
gradually moved from gold-standard invasive right
heart catheterization to multiple speciﬁc echocardiographic parameters. The Mayo Clinic Criteria [2]
selected ﬁve principal echocardiographic variables,
all independently associated with surgically proven
constrictive pericarditis. Apart from the well-recognized respiration-related ventricular septal shifts
and preserved or increased medial mitral annular e’
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Figure 3. Diastolic hepatic vein ﬂow reversal at end expiration, which is a speciﬁc sign for constrictive physiology, in color M-mode and pulsed wave
doppler. The bottom picture shows normalization of hepatic vein inﬂow to predominantly antegrade direction after treatment.

velocity, hepatic vein expiratory diastolic ﬂow
reversal has gained its place as one of the good differentiators with other cardiomyopathies e.g.,
restrictive cardiomyopathy. In our case, the transient
nature of inﬂamed pericardium and the expectation
of rapid response to corticosteroids led to the
cautious omission of right heart catherization, which
may prove difﬁcult to perform in acutely ill patients.
The addition of corticosteroids in tuberculous
pericarditis with effusion received a Class IIb
(Level C) evidence in the 2015 European Society of
Cardiology Guideline [3]; while the 2016 American

Thoracic Society Clinical Practice Guideline
advised against routine corticosteroid therapy for
tuberculous pericarditis [4], citing low quality evidence of beneﬁt [5,6]. However, we elected to start
corticosteroids in this case due to biochemical and
imaging evidence of severe inﬂammation, and
tapered off rapidly once clinical improvement was
seen, to avoid the side effects of prolonged steroid
therapy [7].
This case report has illustrated timely diagnosis of
Mycobacterium tuberculosis infection causing effusiveconstrictive pericarditis, with multiorgan dysfunction.
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